证券代码：603998 证券简称：方盛制药 公告编号：2026-010 湖南方盛制药股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: ●湖南方盛制药股份有限公司（以下简称"公司"）控股股东暨实际控制人张庆华先生办理完成了875万股 （占公司总股本的1.99%）股份质押手续； ●截至本公告披露日，张庆华先生直接持有公司的股份总数为156,019,500股，占公司股份总数 （439,081,360股）的35.53%；张庆华先生质押的公司股份总数为64,075,200股（含本次增加质押的股 份），占其直接持有公司股份总数的41.07%，占公司股份总数的14.59%；张庆华先生控股的湖南开舜 投资咨询有限公司之控股子公司长沙共盛产投咨询有限公司（原"泰州共生创业投资管理有限公司""泰 州共生咨询有限公司"，以下简称"共盛产投"）持有公司股份数为9,131,807股，共盛产投质押的公司股 份总数为0股；张祖嵘女士持有公司股份数423,300股，张祖嵘女士质押的公司股份总数为0股 ...

Group 1 - Company Fangsheng Pharmaceutical announced on February 11, 2026, that its controlling shareholder and actual controller, Mr. Zhang Qinghua, has completed the procedures for pledging part of his shares, with a total of 8.75 million shares pledged [1] - The announcement indicates a significant movement in the company's shareholding structure, which may impact investor sentiment and stock performance [1] Group 2 - The industry is witnessing a surge in stock prices related to film and video production, driven by advancements in AI technology, particularly a new Chinese video model capable of generating 15-second videos from a few prompts [1] - This technological innovation is being referred to as the "strongest on the planet," suggesting a competitive edge for companies involved in the film and entertainment sector [1]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2026-010 湖南方盛制药股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●湖南方盛制药股份有限公司（以下简称"公司"）控股股东暨实际控制人张庆华 先生办理完成了875万股（占公司总股本的1.99%）股份质押手续； ●截至本公告披露日，张庆华先生直接持有公司的股份总数为156,019,500股，占公 司股份总数（439,081,360股）的35.53%；张庆华先生质押的公司股份总数为64,075,200 股（含本次增加质押的股份），占其直接持有公司股份总数的41.07%，占公司股份总数 的14.59%；张庆华先生控股的湖南开舜投资咨询有限公司之控股子公司长沙共盛产投咨 询有限公司（原"泰州共生创业投资管理有限公司""泰州共生咨询有限公司"，以下 简称"共盛产投"）持有公司股份数为9,131,807股，共盛 ...

方盛制药公告称，2月11日，控股股东暨实控人张庆华完成875万股（占总股本1.99%）质押手续，用于 置换将到期融资。截至公告披露日，张庆华直接持股1.56亿股，占总股本35.53%，累计质押6407.52万 股，占其直接持股的41.07%，占总股本14.59%。张庆华及其一致行动人合计持股1.66亿股，累计质押 6407.52万股，占持股总数38.70%。其整体质押风险可控，不存在平仓风险，本次质押对公司经营、治 理等无重大不利影响。 ...

证券日报网讯 2月10日，方盛制药在互动平台回答投资者提问时表示，公司董事会、管理层高度重视市 值维护，已将市值管理纳入部分高级管理人员绩效考核指标。公司将不断完善信息披露机制、加大与投 资者沟通力度，增强投资者对公司的直观认知，传递公司价值；此外，公司严格执行积极、稳定的现金 分红政策，回报全体股东。公司坚持专注于主业的长期可持续发展，通过不断加强经营管理等各项工 作，推动公司持续稳定发展、不断创造价值，以公司的高质量发展积极回报广大投资者。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the news is the release of the "Implementation Plan for the High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" by eight departments, which aims to establish a collaborative development system for the entire industry chain by 2030, enhancing supply capabilities and technological breakthroughs [1] - The plan emphasizes the importance of digital transformation and green transition in the traditional Chinese medicine industry, with leading companies accelerating the construction of smart factories and upgrading production processes [1] - Guangzhou Pharmaceutical Group's Baiyunshan Zhongyi Pharmaceutical was recognized as the only traditional Chinese medicine manufacturer in the "2025 Advanced Intelligent Factory List" due to its systematic breakthroughs in digital transformation [1] Group 2 - The research and development vitality of traditional Chinese medicine companies is being released, with several innovative Class 1 traditional Chinese medicine products expected to be approved for market launch in 2025, including Jiangsu Kangyuan Pharmaceutical's and Jianmin Pharmaceutical's products [2] - Hunan Fangsheng Pharmaceutical has stated that the implementation plan will significantly promote the development of innovative traditional Chinese medicine, and the company plans to increase investment in this area to strengthen its core competitiveness [2] - Local governments are also leveraging industrial funds to attract social capital, with Yunnan Province establishing a 10 billion yuan traditional Chinese medicine industry development fund to enhance the industry ecosystem [2] Group 3 - Since 2025, the traditional Chinese medicine sector has faced performance pressure due to weak sales in pharmacy and hospital channels, leading to a divergence in the performance of listed companies [3] - The OTC (over-the-counter) sector's leading companies have shown resilience, and the industry is undergoing a painful transition in its development model, with a focus on diversified channels and high clinical value being crucial for future success [3] - The implementation plan supports the cultivation of leading enterprises and encourages the establishment of industrial funds, aiming for a healthy ecosystem that integrates large, medium, and small enterprises [3]

Group 1 - The core point of the announcement is that Hunan Fangsheng Pharmaceutical Co., Ltd.'s subsidiary, Guangdong Fangsheng Ronghua Pharmaceutical Co., Ltd., has received a Drug Production License from the Guangdong Provincial Drug Administration, allowing it to act as the marketing authorization holder for the drug Riluzole Tablets [1][2] - The Drug Production License is valid until January 26, 2031, and the production address is located in Changsha, Hunan Province, with the entrusted product being Riluzole Tablets [1] - The license is expected to help the company and its subsidiary integrate and allocate production and sales resources, improve capacity utilization, and reduce production costs [2] Group 2 - The short-term impact of obtaining the Drug Production License on the company's performance is not expected to be significant [2] - The pharmaceutical industry is characterized by uncertainties due to market conditions, industry policies, and supply-demand relationships, which can affect the production and sales of pharmaceutical products [2]

证券日报网讯 2月5日，方盛制药发布公告称，公司控股子公司广东方盛融华药业有限公司近日获广东 省药品监督管理局颁发的《药品生产许可证》，同意其作为上市许可持有人，公司受托生产瑞卢戈利 片，有效期至2031年1月26日。 （文章来源：证券日报） ...

Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received a Drug Production License from the Guangdong Provincial Drug Administration for its subsidiary, Guangdong Fangsheng Ronghua Pharmaceutical Co., Ltd., allowing it to act as the marketing authorization holder for RuLuGuoLi tablets [1] Group 1 - The acquisition of the Drug Production License will help the company and its subsidiary integrate and allocate production and sales resources [1] - This license is expected to improve capacity utilization and reduce production costs for the company [1] - The short-term impact on the company's performance is not expected to be significant following the receipt of the Drug Production License [1]